Trial Profile
A Single Dose Bioequivalence Study Comparing the Commercial Tablet Formulation to the Clinical Tablet of Bosutinib in Healthy Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Dec 2009
Price :
$35
*
At a glance
- Drugs Bosutinib (Primary)
- Indications Breast cancer; Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours
- Focus Pharmacokinetics
- Sponsors Wyeth
- 03 Sep 2009 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 03 Sep 2009 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.
- 15 Jul 2009 New trial record